Patent intelligence · US
US 12208092
Compositions and methods for administering paltusotine to patients with hepatic impairment
Compositions and methods for administering paltusotine to patients with hepatic impairment
Patent details — US 12208092
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 28, 2025
- Expiration
- Jan 23, 2045
- Applicant
- CRINETICS PHARMACEUTICALS, INC.
- Claims
- 27
- CPC classes
- A61K, A61K31/381, A61K31/4709, A61K9/0053
Quick answer
US 12208092 (Compositions and methods for administering paltusotine to patients with hepatic impairment) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CRINETICS PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/381, A61K31/4709, A61K9/0053, A61K9/2013, A61K9/2018
More from CRINETICS PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12280046
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
granted -
US 12134610
Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
granted -
US 11957674
Formulations of a somatostatin modulator
granted -
US 11834462
Somatostatin modulators and uses thereof
granted -
US 11773076
Crystalline forms of a somatostatin modulator
granted -
US 11608335
Somatostatin modulators and uses thereof
granted -
US 11566015
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
granted
Frequently asked questions
What is US patent 12208092?
US 12208092 (Compositions and methods for administering paltusotine to patients with hepatic impairment) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12208092?
CRINETICS PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 12208092 expire?
Our index shows an expiration date of Jan 23, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.